TD Cowen highlights this stock as a best SMID-cap idea with multiple 2026 catalysts
Tweet Send to a Friend
Investing.com-- TD Cowen named a gene therapy company one of its best small- and mid-cap ideas for 2026, reiterating its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
